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RESUMEN  
La insuficiencia cardiaca ocurre debido a la disminución de la contractilidad cardiaca (sístole) o cuando el 
corazón es incapaz de relajarse (diástole).  A pesar del costo del sufrimiento en el cuidado de la insuficiencia 
cardiaca se mantiene con disfunción sistólica, en la última década se ha reconocido que aproximadamente el 
50% de la población tiene el otro tipo de insuficiencia cardiaca, aquella que ocurre con disfunción diastólica.   
El tratamiento está enfocado a abordar tres elementos: (1) al control tanto de la presión sistólica como la 
diastólica. (2) restaurar y mantener el ritmo sinusal en pacientes sintomáticos con fibrilación y fluter atrial, (3) 
el control de la congestión de los fluidos, la sobrecarga.  El propósito de este estudio es el de brindar una revisión 
al diagnóstico y tratamiento de la insuficiencia cardiaca diastólica. 
Palabras claves: insuficiencia cardiaca diastólica, disfunción diastólica, insuficiencia cardiaca, fracción de 
eyección.  
ABSTRACT 
 Heart failure can occur from decreased contractility of the heart (systolic) or the heart’s inability to relax 
(diastolic). Although the cost of burden in the care of heart failure remains with systolic dysfunction, the past 
decade has recognized that approximately 50% of the population has the other type of  heart failure (HF), 
diastolic dysfunction. The focus of treatment in diastolic dysfunction is threefold: (1) to control both systolic 
and diastolic blood pressure, (2) to restore and maintain sinus rhythm in symptomatic patients with atrial 
fibrillation and atrial flutter, and (3) to control congestion and fluid overload. The purpose of this paper is to 
provide a review of the diagnosis and treatment of diastolic heart failure.  
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 Heart failure (HF) is a progressive 
disease that affects approximately 5 
million Americans, and this number 
continuous to grow with the aging 
population (American Heart Association, 
2010, Brookes, L & Solomon, Sd., 2006). 
Despite advances in medical therapy, HF 
is associated with high morbidity, 
mortality, and rehospitalization (≤ 30 
days) rates (American Heart Association, 
2010). The cost of burden of direct and 
indirect care of someone with HF is an 
estimated $39B per year (American Heart 
Association, 2010,). Although the current 
focus of stringent care is with systolic HF, 
the past decade has recognized that 
approximately 40-50% of the population 
has diastolic dysfunction, and that the 
morbidity rate including rehospitalization 
is similar to those with systolic HF 
(Brookes, L & Solomon, Sd.,2006,  
Hamlin, SK. y Cols., 2004, Kuznetsova, L, 
y Cols., 2010).  This article will review the 





Types OF HF 
 
There are currently two different 
types of HF – systolic, which can occur 
from decreased contractility of the heart, 
and diastolic, in which the heart is unable 
to relax (Gutierrez, C, &Blachard, Dg., 
2004).  Initially, identifying the left 
ventricular ejection fraction (LVEF) 
distinguishes between systolic HF (SHF) 
and diastolic HF (DHF). In systolic HF, 
the left ventricular ejection fraction 
(LVEF) is ≤ 40% whereas in diastolic HF 
(DHF), the LVEF is ≥ 45%. The terms 
DHF, HF with normal LVEF, HF with 
preserved LVEF (PLVEF), and diastolic 
dysfunction (DD) have been used 
interchangeably. By definition, DD refers 
to the abnormalities noted in ventricular 
filling and relaxation, whereas DHF is a 
clinical syndrome as evident by volume 
overload and decompensation often 
requiring hospitalization (Hamlin, SK. y 
Cols.,   2004).   
 
Diastole is a process of passive 
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(Aurigemma, y Cols.  2004).   In DHF, 
there is impaired relaxation, which 
increases stiffness of the LV causing 
reduced chamber compliance and reduced 
filling time (Gutierrez, C, &Blachard, Dg., 
2004 Kuznetsova, L, y Cols., 2010), 
Aurigemma, G. P. y  Gaasch, W. H, 2004, 
Linfield, J,  y Cols., 2010). Similar to SHF, 
the neurohormonal cascades including the 
renin-angiotensin (RAS) and the 
sympathetic nervous (SNS) systems are 
activated in DHF (Linfield, J,  y Cols., 
2010).  
 
Stages of HF 
 
 In 2005, a new staging system was 
developed to show the development and 
progression of the disease (Hun, 2005). 
The first two stages (Stages A and B) 
describes those patients that do not have 
HF but are at high risk of developing the 
disease. Stages C and D are those patients 
who have a definitive diagnosis of HF. 
Stage A are those who have risk factors 
associated with the development of HF, 
such as hypertension; whereas Stage B are 
those with structural heart disease but are 
asymptomatic (Hun, 2005). Stage C 
patients are those who currently or 
previously had symptoms of HF, and those 
patients in Stage D are those characterized 
by refractory HF who may require 
specialized intervention (Hun, 2005).  
 
Causes of DHF 
 
Hypertensive LVH is the most 
common cause of DHF, however coronary 
artery disease and diabetes are known to be 
associated with the development of DD 
(Gutierrez, C, &Blachard, Dg., 2004, 
Aurigemma, G. P. y  Gaasch, W. H, 2004, 
Linfield, J,  y Cols., 2010),Satpathy, C, y 
Cols., 2006). Valvular disorders, mainly 
aortic stenosis, obesity and aging are also 
common causes (Satpathy, C, y Cols., 
2006). Cardiomyopathy (genetic, post-
partum, viral, and drug and/or radiation) 
and infiltrative myopathy are two other 
disease processes that may lead to DD 
(Linfield, J,  y Cols., 2010)). Common 
precipitating factors of include volume 
overload, tachycardia, arrhythmia 
including atrial fibrillation, increased salt 
intake and use of non-steroidal drugs 
(Satpathy, C, y Cols., 2006). Other 
uncommon causes of DHF include 
pericardial disorder, and conditions such 
as anemia and presence of AV fistula 
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(Linfield, J,  y Cols., 2010, Satpathy, C, y 




 Obtaining a thorough clinical 
history and physical exam remains crucial 
in making the diagnosis of DHF.  Patients 
with DHF may have the same signs and 
symptoms similar to someone with SHF. 
However, in patients with DHF, the 
symptom of decreased exercise tolerance 
because of increased LV diastolic and 
pulmonary venous pressures (Aurigemma, 
G. P. y  Gaasch, W. H, 2004).  This is as a 
result of decreased lung compliance and 
inadequate cardiac output during exercise 
thus leading to leg fatigue and use of 
respiratory accessory muscles 
(Aurigemma, G. P. y  Gaasch, W. H, 
2004).   
A European study group proposed 
a classification schema for diagnosing 
DHF based on the degree of diagnostic 
certainty from “definite” via “probable” to 
“possible” (Kraajj, D. J., Cols. 2002).   A 
definitive diagnosis of DHF has evidence 
of congestive HF (CHF), objective 
evidence of normal LV systolic function 
(LVSF) of 50% or more within 72 hours of 
event, and LV diastolic dysfunction, based 
upon abnormal LV relaxation or filling or 
distensibility indices on cardiac 
catheterization (Kraajj, D. J., Cols. 2002).  
A probable diagnosis of DH has the same 
evidence of CHF and evidence of normal 
LVSF, however has no conclusive 
information on LV diastolic function 
(Kraajj, D. J., Cols. 2002). In possible 
DHF, have evidence of CHF, and LVEF of 
≥ 50% but not within the 72 hours of event 
(Kraajj, D. J., Cols. 2002).  Other criteria 
for assessing and diagnosing SHF and 
DHF are available from the American 
College of Cardiology, Duke, and Boston.  
 
As mentioned earlier, since 
patients with DHF can also present with 
signs and symptoms similar to systolic HF, 
diagnosis can established by quantifying 
LVEF, volume, dimensions, and thickness 
using imaging techniques such as 
echocardiogram, cardiac magnetic 
imaging or cardiac catheterization 
(Hamlin, SK. y Cols.,   2004,Galderisi, M. 
(2005). Echocardiography should be 
considered first over these other 
techniques simply because it is the 
cheapest and the least invasive to the 
person. Other information that can be 
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obtained from these tests includes valvular 
function, filling patterns, cardiac anatomy, 
and left atrial enlargement in the absence 
of atrial fibrillation (Linfield, J,  y Cols., 
2010). It is recommended that careful 
attention to differential diagnosis 
including ischemia through 
echocardiogram, electrocardiogram, stress 
imaging, and cardiac catheterization 
because treatment to various cardiac 
disorders may be different (Linfield, J,  y 
Cols., 2010).   
 
 The use of B-type natriuretic 
peptide (BNP) or NT-proBNP may assist 
health care providers to determine whether 
dyspnea is due to heart failure or non-
cardiac causes (Linfield, J,  y Cols., 2010). 
These peptides are released from the LV in 
response to increased volume and pressure 
(Linfield, J,  y Cols., 2010). It is important 
however to note that elevated levels of 
BNP or NT- proBNP do not differentiate 
between systolic and diastolic dysfunction 
(Gutierrez, C, & Blachard, Dg., 2004 , 
Hamlin, SK. y Cols.,   2004, Linfield, J,  y 
Cols., 2010). Likewise, levels of BNP and 
NT- proBNP also vary by age, gender, 
weight, and renal function (Linfield, J,  y 
Cols., 2010).  
 A diagnostic algorithm was 
developed in the 2010HFSA guidelines for 
patients with PLVEF (Figure 1). This 
algorithm is categorized whether the 
patient has a dilated LV or not (Linfield, J,  
y Cols., 2010). A dilated LV can result in 
either valvular or non-valvular disease 
(Aurigemma, G. P. y  Gaasch, W. H, 
2004). In non-dilated LV, the presence of 
right ventricular dysfunction and LV 
thickness, normal or increased, can lead to 




 The goals of treatment in DHF 
include: (1) control congestion or fluid 
overload, (2) control blood pressure both 
systolic and diastolic in accordance with 
published guidelines, and (3) restore and 
maintain sinus rhythm in patients with 
symptomatic atrial fibrillation or atrial 
flutter but measures should be 
individualized (Linfield, J,  y Cols., 
2010,Kantharia, BK. , 2010).  Thiazide 
and loop diuretics are recommended if 
clinical evidence of fluid overload or overt 
congestion is present (Linfield, J,  y Cols., 
2010). Treatment with loop diuretic should 
be implemented if the use of thiazide 
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diuretic is not adequate (Linfield, J, y 
Cols., 2010). Excessive diuresis, however 
should be avoided to prevent orthostatic 
changes, worsening renal function, and 
electrolytes abnormalities (Linfield, J, y 
Cols., 2010). Additionally, sodium and 
fluid restrictions to ≤ 2L/day should be 
done when hyponatremia is present 
(sodium level is <130 mg/dl). Likewise, 
ultrafiltration may also be considered if 
diuresis is not effective (Linfield, J, y Cols. 
2010).     
 
 Since hypertension is the most 
common cause of DHF, drug therapies 
include the use of angiotensin converting 
enzyme inhibitor (ACE-1) or angiotensin 
receptor blockers (ARB), beta blockers, 
and calcium channel blockers (Linfield, J,  
y Cols., 2010). The use of ACE-1 should 
be considered in all patients with Diabetes 
Mellitus DD who have established 
cardiovascular disease or DM plus one 
additional risk factor. Additionally, ARB 
should be considered to those who are 
intolerant of ACE-1 (Linfield, J,  y Cols., 
2010). Beta-blockers is recommended to 
those patients who have prior myocardial 
infarction, those with hypertension, and 
atrial fibrillation requiring ventricular rate 
control (Linfield, J. y Cols., 2010). 
Calcium channel blockers (CCB) should 
be considered in patients with DD and 
symptom-limiting angina, and 
hypertension (Linfield, J, y Cols., 2010). 
Likewise, diltiazem or verapamil are the 
CCBs that should be considered in patients 
with DD and atrial fibrillation who require 
ventricular rate control and those who are 
unable to tolerate beta blockers (Linfield, 
J.  y Cols., 2010).  
 
 Atrial fibrillation and atrial flutter 
are not uncommon in the setting of DHF 
(Hun, 2005). Patients with HF are 
generally at an increased risk to 
developing atrial fibrillation and atrial 
flutter because of increased end-diastolic 
pressures and atrial distention (Gutierrez, 
C, & Blachard, Dg., 2004, Kuznetsova, L, 
y Cols., 2010).  The new HFSA guidelines 
considered that it may be reasonable to 
attempt to restore to sinus rhythm in 
patients who remained symptomatic after 
adequate rate control (Linfield, J.y Cols., 
2010). Digoxin is the drug frequently use 
for rate control. The use of amiodarone 
and dofetilide has shown to increase 
conversion to sinus rhythm in some 
subsets of patients with HF (Linfield, J. y 
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Cols., 2010). Likewise, ablative therapy 
may be considered in patients with atrial 
fibrillation to improve symptoms 





HF is a growing epidemic and 
DHF is slowly becoming recognized as a 
major health care issue. As health care 
providers, we are at the frontline of taking 
care of these patients who may potentially 
unbeknown to us to have DD and DHF, 
particularly those with hypertension. 
Understanding the problem is just the 
beginning. Knowing how to diagnose and 
initiate treatment early is important to 
delay the progression of the condition to 
systolic dysfunction, which is irreversible. 
Becoming familiar with the guidelines can 
help or can assist health care providers 
including nurse practitioners to deliver 
evidenced-based quality of care. In the 
end, it is our responsibility as healthcare 
professionals to create plans of care to 
increase adherence of these patients to 


















    Valvular disorder (atrial regurgitation, mitral regurgitation) 
Dilated LV   
     
    Non-valvular disorder (high output HF) 
          
           Mitral obstruction (mitral   
    Normal thickness  stenosis, atrial myoma)  
 
    No mitral obstruction 
- Pericardialdisease (tamponade, 
constriction) 
Non-dilated LV      - No pericardial disease 
 
         
Inducible ischemia     Non-inducible ischemia 
        
 
        Low QRS voltage 
    Increased thickness    (infiltrative myopathy)  
 
     
        Normal or  QRS voltage 
        (hypertrophic disease) 
 
       
      No Aortic valve disease      Aortic valve disease 
 
    
No history of HTN or PE   Hypertensive history of PE 
    Hypertrophic CM    Hypertensive hypertrophic CM  
    Fabry disease 
 
           
                 Pulmonary HTN  
 Right ventricular dysfunction 
 
     Isolatedpredominant 
           RVMI  
 
 
Figure 1.Diagnostic algorithm for HF with PSF. Adapted with modification from the 2010 HFSA Comprehensive HF 
Practice Guidelines.J Cardiac Failure, 16(6). CM = cardiomyopathy; PE= pulmonary embolism; RVMI = 
right ventricular myocardial infarction.  
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